A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

Conditions

• Bronchiectasis With Pseudomonas Aeruginosa Colonization

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• AZD0292 — BIOLOGICAL
  AZD0292 high-dose or low-dose administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.
• Placebo — OTHER
  Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments.

Study Details

AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

Key Dates

Start date

Nov 6, 2025

Status verified

Jun 2026

Primary completion

Dec 9, 2027

Completion

Jun 14, 2028

Study Design

Enrollment

435 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Arms

• Experimental: High-dose
  High-Dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments.
• Experimental: Low-dose
  Low-dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments.
• Placebo Comparator: Placebo
  Placebo administered starting on Day 1, subsequent administrations per schedule of assessments.

Primary Outcome Measure

Annualized rate of exacerbations over a variable follow-up time [ Time Frame: Min 28 weeks, max 52 weeks ]

Central Contacts

• AstraZeneca Clinical Study Information Center
  1-877-240-9479
  [email protected]

Locations (25)

Find similar trials in Orange, CA